The Global Biologics CDMO Market is forecast to grow by $13.26 bn during 2022-2027, accelerating at a CAGR of 13.97% during the forecast period
NEW YORK, Feb. 27, 2023 /PRNewswire/ -- Global Biologics CDMO Market 2023-2027
The analyst has been monitoring the biologics CDMO market and is forecast to grow by $13.26 bn during 2022-2027, accelerating at a CAGR of 13.97% during the forecast period. Our report on the biologics CDMO market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
Read the full report: https://www.reportlinker.com/p06227645/?utm_source=PRN
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the availability of cost-efficient resources in emerging markets, strong research and development pipeline of biologics therapeutics, and a growing need to focus on core competencies.
The biologics CDMO market is segmented as below:
By Type
- Mammalian
- Microbial
By Product Type
- Biologics
- Biosimilars
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the advent of big data as one of the prime reasons driving the biologics CDMO market growth during the next few years. Also, strategic alliances and partnerships with pharma companies and increasing approvals for new molecules and biosimilars will lead to sizable demand in the market.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the biologics CDMO market covers the following areas:
- Biologics CDMO market sizing
- Biologics CDMO market forecast
- Biologics CDMO market industry analysis
This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biologics CDMO market vendors that include 3P BIOPHARMACEUTICALS S.L.U., AbbVie Inc., AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Bora Pharmaceuticals Co. Ltd., Catalent Inc., Cytovance Biologics, Evonik Industries AG, FUJIFILM Holdings Corp, Grifols SA, JRS PHARMA GmbH and Co. KG, JSR Corp., Kemwell Biopharma Pvt. Ltd., KLOCKE GROUP, Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., Toyobo Co. Ltd., and WuXi Biologics Cayman Inc. Also, the biologics CDMO market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Read the full report: https://www.reportlinker.com/p06227645/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
![](https://rt.prnewswire.com/rt.gif?NewsItemId=NY24304&Transmission_Id=202302271210PR_NEWS_USPR_____NY24304&DateId=20230227)
Share this article